While using compression socks for neuropathy pain isn’t new, there’s an innovation in the space, DNS or Dermatone Neuropoint Socks, that we take a look at in this article.
At a high level, DNS socks have a technology & pattern woven into them that can send a signal to the brain which may help reduce pain associated with diabetic neuropathy. While additional research is needed, early data is encouraging and we summarize the findings of one of the scientific studies below.
Painful Diabetic Neuropathy, or PDN, is a type of nerve damage that can significantly impact daily routines. Patients commonly report pain similar to a burning, electrical or stabbing sensation in the feet and legs.
The full study, conducted by Dr. Stephan Taylor and Jason Devos and published by Voxx Life, is titled: “Effect of Dermatone Neuropoint Activating Socks on Painful Diabetic Neuropathy Pain in Feet.”
The study found that after one week of wearing these socks, the average pain level reported by 1,000 neuropathy patients went from a 7 (severe) to a 2 (mild).
“The initial findings are promising as over 95% of the subjects saw a significant reduction in pain after 1 week of usage when compared to a Regular Diabetic Sock.”– Dr. Stephan Tayor
1,000 people aged 35-72 years old with all of the following:
a) Painful diabetic neuropathy pain score > 4 for at least 90 days
b) Diagnosed with diabetes for > 10 years
c) No foot condition that would limit the ability to wear the socks
d) Typically wears regular diabetes-approved socks
Study Duration: > 6 months (circa 2016/2017)
Step 1: 1,000 diabetes patients completed a pain assessment form with the help of a Pain Management Expert
Step 2: They then regularly wore Dermatone Neuropoint Socks (developed by Voxx Life)
Step 3: They then came back to the clinic the following week and reported their pain level to the expert
950+ of the 1,000 patients reported feeling better / less pain.
“The initial findings are promising as over 95% of the subjects saw a significant reduction in pain after 1 week of usage when compared to a Regular Diabetic Sock.”
To explain “significant reduction in pain”, the study states that 76.9% of pain scores using the Universal Pain Scale were reduced to a “2” or lower, which meant that the pain was manageable / can be ignored.
All patients entering the study reported at least a pain level of “4” when starting out, which is defined as “Pain that interferes with tasks.”
Graphs & Charts
Here is what the Universal Pain Scale / Assessment Tool looks like:
Everyone entering the study reported at least a level of “4” at the start with the mean score reported nearing a “7” or severe. One week later, 95% of those patients reported that their pain was reduced, typically to a level of “2” or lower, with the mean level reported as 1.806 or mild.
Here is a breakdown of the pain levels reported at the start of the study:
And a breakdown of the pain levels reported one week later after wearing the neuropoint activating socks (developed by Voxx):
Which gets us back to the combined chart shown at the top of this article:
To determine average change in pain scores, there were a series of statistical tests run that you can check out in the full report, but the summary of the data is:
- 18 or 1.8% of patients reported a 10% drop in pain
- 61 or 6.1% of patients reported a 20% drop in pain
- 113 or 11.3% of patients reported a 30% drop in pain
- 136 or 13.6% of patients reported a 40% drop in pain
- 145 or 14.5% of patients reported a 50% drop in pain
- 143 or 14.3% of patients reported a 60% drop in pain
- 147 or 14.7% of patients reported a 70% drop in pain
- 122 or 12.2% of patients reported an 80% drop in pain
- 39 or 3.9% of patients reported a 90% drop in pain
- 17 or 1.7% of patients reported a 100% drop in pain
This study looked specifically at Dermatone Neuropoint Socks (DNS) developed by Voxx Sports and the effect they may or may not have had on Painful Diabetic Neuropathy (PDN) foot pain.
The resulting data led the scientists conducting the study to report that this “phenomenon” needs to be further studied over a longer period of time, but initial data “shows promise in offering PDN patients an alternative for pain management.”